Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CARA NASDAQ:ENTX NASDAQ:GNLX NASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCARACara Therapeutics$15.19$8.13▼$19.08$24.33M0.4122,224 shs237,144 shsENTXEntera Bio$1.93-0.5%$1.93$1.50▼$2.79$88.59M1.5265,206 shs21,517 shsGNLXGenelux$3.33-5.7%$3.32$1.95▼$5.89$133.34M-0.3290,274 shs101,063 shsSKYESkye Bioscience$3.50+0.6%$3.76$1.14▼$7.11$107.84M2.21289,109 shs159,367 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCARACara Therapeutics0.00%0.00%0.00%0.00%+24.71%ENTXEntera Bio-0.52%-0.52%-4.46%+5.18%+16.97%GNLXGenelux-5.67%-11.90%-5.67%+34.82%+68.18%SKYESkye Bioscience+0.57%+6.38%-3.05%+75.18%-42.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCARACara TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AENTXEntera Bio0.895 of 5 stars2.03.00.00.02.20.80.0GNLXGenelux1.8291 of 5 stars3.52.00.00.03.50.00.0SKYESkye Bioscience1.5655 of 5 stars3.62.00.00.01.50.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCARACara Therapeutics 0.00N/AN/AN/AENTXEntera Bio 4.00Strong Buy$10.00418.13% UpsideGNLXGenelux 3.00Buy$20.33510.61% UpsideSKYESkye Bioscience 3.14Buy$15.50342.86% UpsideCurrent Analyst Ratings BreakdownLatest CARA, GNLX, SKYE, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/15/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/14/2025SKYESkye BioscienceEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.008/11/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/23/2025GNLXGeneluxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025SKYESkye BioscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00ENTXEntera Bio$180K489.58N/AN/A$0.38 per share5.08GNLXGenelux$10K12,577.41N/AN/A$0.63 per share5.29SKYESkye BioscienceN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/AENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)GNLXGenelux-$29.87M-$0.86N/AN/AN/AN/A-107.47%-83.14%11/13/2025 (Estimated)SKYESkye Bioscience-$26.57M-$1.06N/AN/AN/AN/A-76.03%-69.20%N/ALatest CARA, GNLX, SKYE, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/A8/7/2025Q2 2025GNLXGenelux-$0.22-$0.20+$0.02-$0.20N/AN/A8/7/2025Q2 2025SKYESkye Bioscience-$0.34-$0.44-$0.10-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCARACara TherapeuticsN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AGNLXGeneluxN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCARACara TherapeuticsN/A4.774.71ENTXEntera BioN/A10.4710.47GNLXGeneluxN/A4.184.18SKYESkye BioscienceN/A6.096.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCARACara Therapeutics44.66%ENTXEntera Bio14.11%GNLXGenelux37.33%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipCARACara Therapeutics3.10%ENTXEntera Bio10.38%GNLXGenelux8.80%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCARACara Therapeutics804.57 million4.43 millionOptionableENTXEntera Bio2045.66 million40.92 millionOptionableGNLXGenelux1037.77 million34.45 millionNot OptionableSKYESkye Bioscience1130.99 million29.59 millionOptionableCARA, GNLX, SKYE, and ENTX HeadlinesRecent News About These CompaniesSkye Bioscience to host KOL event on CBeyond Phase 2a clinical data readoutAugust 27 at 10:05 PM | msn.comSkye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data ReadoutAugust 27 at 7:00 AM | globenewswire.comSkye Bioscience, Inc. (NASDAQ:SKYE) Receives $15.50 Average PT from AnalystsAugust 25, 2025 | americanbankingnews.comSkye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by AnalystsAugust 24, 2025 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Major Shareholder 5Am Partners Vii, Llc Sells 60,956 SharesAugust 23, 2025 | insidertrades.comSkye Bioscience, Inc. to Present at Multiple Investment and Medical Conferences in September 2025August 21, 2025 | quiverquant.comQSkye Bioscience to Participate in Upcoming Investment and Medical ConferencesAugust 21, 2025 | globenewswire.comSkye Bioscience (NASDAQ:SKYE) Upgraded by Evercore ISI to Strong-Buy RatingAugust 18, 2025 | marketbeat.comEvercore ISI Group Initiates Coverage of Skye Bioscience (SKYE) with Outperform RecommendationAugust 16, 2025 | msn.comEvercore starts Skye Bioscience at Outperform on nimacimab potentialAugust 14, 2025 | msn.comSkye Bioscience initiated with an Outperform at Evercore ISIAugust 14, 2025 | msn.comSkye Bioscience, Inc. (NASDAQ:SKYE) is Altium Capital Management LLC's 9th Largest PositionAugust 14, 2025 | marketbeat.comSkye Bioscience Earnings Call: Positive Outlook Amid ChallengesAugust 13, 2025 | msn.comSkye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platformAugust 9, 2025 | msn.comSkye Bioscience Inc (SKYE) Q2 2025 Earnings Call Highlights: Promising Trial Progress Amid ...August 9, 2025 | finance.yahoo.comSkye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comSkye Bioscience Reports Second Quarter 2025 Financial Results and Business UpdateAugust 7, 2025 | globenewswire.comWe Think Skye Bioscience (NASDAQ:SKYE) Needs To Drive Business Growth CarefullyAugust 6, 2025 | finance.yahoo.comSkye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025July 30, 2025 | globenewswire.comSKYE Stock Price Quote | MorningstarJuly 11, 2025 | morningstar.comMSkye Bioscience, Inc. (SKYE) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCARA, GNLX, SKYE, and ENTX Company DescriptionsCara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Entera Bio NASDAQ:ENTX$1.93 -0.01 (-0.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.92 -0.01 (-0.52%) As of 08/29/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Genelux NASDAQ:GNLX$3.33 -0.20 (-5.67%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.32 0.00 (-0.15%) As of 08/29/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Skye Bioscience NASDAQ:SKYE$3.50 +0.02 (+0.57%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$3.50 0.00 (0.00%) As of 08/29/2025 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
